InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（0 笔）
内部人交易记录
董事已披露买入
2
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the complete record of transactions filed by Lang James Paul, 董事. Officer active across 3 companies, notably OptimizeRx Corp. Cumulatively, 11 filings have been published. Split: 2 buys · 0 sell. Total volume traded: €2.3m. History available since 30 June 2021. The latest transaction was filed on 2 January 2026 (Attribution). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Lang James Paul
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报11 总计
889 股0Restricted Stock UnitsSEC:0001159036-26-000007:0
9,868 股0Common StockSEC:0001628280-25-031022:0
321,408 股@ US$7.603395.8% 占其流量Common StockSEC:0001628280-25-013918:0
标准退出：2025年6月12日 (T+90)
10,061 股0Common StockSEC:0001628280-24-027709:0
4,637 股0Common StockSEC:0001628280-23-029928:0
657 股0Common StockSEC:0001628280-23-010323:0
43,578 股0COMMON STOCKSEC:0001520138-23-000059:0
409 股0Common StockSEC:0001628280-23-000210:0
334 股0Common StockSEC:0001628280-22-025811:0
6,000 股@ US$16.45394.2% 占其流量Common StockSEC:0001213900-22-050556:0
标准退出：2022年11月17日 (T+90)
407 股0Common StockSEC:0001213900-21-035078:0
11 条申报中的 11 条
About Lang James Paul
Lang James Paul is Administrateur at OptimizeRx Corp, Halozyme Therapeutics, INC. and BIOVIE INC. He has 11 filings in total, and across the 11 sampled filings between 2021-06-30 and 2026-01-06, the transactions are buys for EUR 2348988 and no sells, with Levée d'options as the most frequent transaction nature.
